What is ImpediMed?
Founded in 1999 and headquartered in Queensland, Australia, Impedimed is at the forefront of developing and distributing medical devices that utilize bioimpedance spectroscopy (BIS) technology. This technology enables the clinical assessment and monitoring of fluid status in patients without invasive procedures. The company's focus on BIS positions it as a key player in the medical technology sector, addressing critical needs in patient care and management through advanced diagnostic tools. The enterprise-level funding context suggests Impedimed is in a significant growth or scaling phase, likely expanding its market reach and product development capabilities.
How much funding has ImpediMed raised?
ImpediMed has raised a total of $86.9M across 4 funding rounds:
Other Financing Round
$3.4M
Stock Offering
$11.5M
Share Placement
$57M
Other Financing Round
$15M
Other Financing Round (2006): $3.4M with participation from Starfish Ventures
Stock Issuance/Offering (2007): $11.5M, investors not publicly disclosed
Share Placement (2016): $57M, investors not publicly disclosed
Other Financing Round (2025): $15M featuring SWK Holdings and Armentum Partners
Key Investors in ImpediMed
Starfish Ventures
Starfish Ventures is an Australian venture capital manager that specializes in high-growth technology businesses, particularly in information technology and life sciences. They focus on partnering with entrepreneurs to drive company growth through team expansion, product development, and global scaling, aiming for successful exits.
SWK Holdings
SWK Holdings is a life science specialty finance company established in 1996, providing capital solutions to healthcare sector companies, institutions, and inventors globally. Based in Dallas, Texas, they focus on innovative financing for the life sciences industry.
Armentum Partners
Armentum Partners is an investment bank specializing in debt capital advisory for technology and healthcare companies. They offer tailored debt capital solutions across North America, Europe, and Australia, focusing on enhancing financial strategies and supporting client growth objectives.
What's next for ImpediMed?
The recent major strategic investment signals a pivotal moment for Impedimed, likely enabling accelerated research and development, expansion into new markets, and enhancement of its distribution networks. The company's trajectory, marked by consistent capital raises, points towards a strategic push for market leadership in the non-invasive fluid monitoring space. Future endeavors may include further technological advancements in BIS, strategic partnerships, and potential global scaling initiatives to solidify its position as a world leader in this specialized medical device segment.
See full ImpediMed company page
